STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC

Dr. Martin H. Voss provides an analysis of the recent data presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, focusing on the phase 3 STELLAR trial, which evaluates the safety and efficacy of the combination therapy Zanzalintinib and nivolumab in patients with non-clear cell renal cell carcinoma.

EP: 1.Evolving Treatment Standards in Non-Clear Cell RCC

EP: 2.Extended Follow Up of KEYNOTE-B61

EP: 3.Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC

Now Viewing

EP: 4.STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC

1. Please discuss the recent data presented at ASCO 2024 on the phase 3 STELLAR trial
   1. Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study (Abstract TPS4611)

Related Videos